Arabic Arabic English English French French German German
dark

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial

Bristol Myers Squibb today announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to platinum-based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM), regardless of histology. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Industry Veteran Rusty Williams Leads Startup to $50 Million Series A

Next Post

Successful demonstration of BioDrone® platform-based drug delivery and confirmed restoration of the myogenic potential of Prokr1-deficient C2C12 myoblasts

Related Posts
Total
0
Share